{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:20Z","timestamp":1790812820962,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.eururo.2019.04.033","type":"journal-article","created":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T15:43:24Z","timestamp":1557675804000},"page":"142-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019"],"prefix":"10.1016","volume":"76","author":[{"given":"Giorgio","family":"Gandaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Anders","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"S\u00f8nksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2019.04.033_bib0410","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2019.04.033_bib0415","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2019.04.033_bib0420","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2018.10.053","article-title":"Results of prostate cancer screening in a unique cohort at 19 yr of follow-up","volume":"75","author":"Osses","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0425","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schroder","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2019.04.033_bib0430","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/cncr.31178","article-title":"The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials","volume":"124","author":"de Koning","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.04.033_bib0435","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","article-title":"Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial","volume":"68","author":"Arnsrud Godtman","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0440","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2019.04.033_bib0445","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2019.04.033_bib0450","doi-asserted-by":"crossref","first-page":"k3519","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2019.04.033_bib0455","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0460","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2019.04.033_bib0465","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1741-7015-12-26","article-title":"Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen","volume":"12","author":"Vickers","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.eururo.2019.04.033_bib0470","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2012.04.024","article-title":"Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial","volume":"62","author":"Vickers","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0475","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0480","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2019.04.033_bib0485","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2013.06.051","article-title":"Early detection of prostate cancer: European Association of Urology recommendation","volume":"64","author":"Heidenreich","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0490","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","article-title":"Early detection of prostate cancer: AUA guideline","volume":"190","author":"Carter","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0495","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2015.61.6532","article-title":"National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening","volume":"33","author":"Drazer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0500","series-title":"After long decline, death rates from prostate cancer stop falling","author":"Negolita","year":"2018"},{"key":"10.1016\/j.eururo.2019.04.033_bib0505","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cncr.31337","article-title":"PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening","volume":"124","author":"Kearns","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.04.033_bib0510","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/jamaoncol.2016.5465","article-title":"Increase in prostate cancer distant metastases at diagnosis in the United States","volume":"3","author":"Hu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0515","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1001\/jama.2015.14905","article-title":"Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations","volume":"314","author":"Jemal","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2019.04.033_bib0520","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrurol.2016.251","article-title":"The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA","volume":"14","author":"Fleshner","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0525","doi-asserted-by":"crossref","first-page":"663.e1","DOI":"10.1016\/j.urolonc.2017.06.059","article-title":"Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice","volume":"35","author":"Gaylis","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0530","first-page":"77","article-title":"Prostate biopsy characteristics: a comparison between the pre- and post-2012 United States Preventive Services Task Force (USPSTF) prostate cancer screening guidelines","volume":"20","author":"Shah","year":"2018","journal-title":"Rev Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0535","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0540","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement","volume":"319","author":"Force USPST","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2019.04.033_bib0545","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.urology.2015.12.054","article-title":"The Memorial Sloan Kettering Cancer Center recommendations for prostate cancer screening","volume":"91","author":"Vickers","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.04.033_bib0550","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/jnci\/dju366","article-title":"Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data","volume":"107","author":"Heijnsdijk","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2019.04.033_bib0555","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.04.033_bib0560","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer\u201429-year follow-up","volume":"379","author":"Bill-Axelson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.04.033_bib0565","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2019.04.033_bib0570","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bju.14580","article-title":"Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial","volume":"123","author":"Pinsky","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.04.033_bib0575","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMc1515131","article-title":"Reevaluating PSA testing rates in the PLCO trial","volume":"374","author":"Shoag","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.04.033_bib0580","doi-asserted-by":"crossref","first-page":"djv014","DOI":"10.1093\/jnci\/djv014","article-title":"Conceptualizing overdiagnosis in cancer screening","volume":"107","author":"Marcus","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2019.04.033_bib0585","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2011.06.039","article-title":"Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort","volume":"60","author":"Abdollah","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0590","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.04.033_bib0595","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/cncr.25568","article-title":"Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50","volume":"117","author":"Lilja","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.04.033_bib0600","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2016.66.7527","article-title":"Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer","volume":"34","author":"Preston","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0605","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2006.06.9351","article-title":"Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years","volume":"25","author":"Lilja","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0610","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2018.08.032","article-title":"Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in black men","volume":"75","author":"Preston","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0615","doi-asserted-by":"crossref","first-page":"f2023","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case\u2013control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2019.04.033_bib0620","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pros.22925","article-title":"Prostate cancer risk prediction based on complete prostate cancer family history","volume":"75","author":"Albright","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2019.04.033_bib0625","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.juro.2014.03.032","article-title":"Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening","volume":"192","author":"Vertosick","year":"2014","journal-title":"J Urol"},{"issue":"3 Pt 2","key":"10.1016\/j.eururo.2019.04.033_bib0630","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-5347(17)37393-7","article-title":"Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer","volume":"147","author":"Benson","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0635","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/annonc\/mdu525","article-title":"Do prostate cancer risk models improve the predictive accuracy of PSA screening?. A meta-analysis","volume":"26","author":"Louie","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0640","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2017.01.033","article-title":"Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculator for initial prostate biopsy by incorporating the 2014 International Society of Urological Pathology Gleason grading and cribriform growth","volume":"72","author":"Roobol","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0645","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","article-title":"Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculators","volume":"75","author":"Alberts","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0650","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jhealeco.2005.03.002","article-title":"Life expectancy and the value of early detection","volume":"24","author":"Howard","year":"2005","journal-title":"J Health Econ"},{"key":"10.1016\/j.eururo.2019.04.033_bib0655","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa1201637","article-title":"Quality-of-life effects of prostate-specific antigen screening","volume":"367","author":"Heijnsdijk","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.04.033_bib0660","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2016.02.032","article-title":"The problem is not what to do with indolent and harmless prostate cancer\u2014the problem is how to avoid finding these cancers","volume":"70","author":"Gandaglia","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0665","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","article-title":"Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging?. A systematic review of the literature","volume":"68","author":"Futterer","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0670","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2019.04.033_bib0675","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.04.033_bib0680","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eururo.2015.12.006","article-title":"Role of magnetic resonance imaging in prostate cancer screening: a pilot study within the Goteborg randomised screening trial","volume":"70","author":"Grenabo Bergdahl","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0685","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2017.06.019","volume":"73","author":"Alberts","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0690","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50\u201369 years (STHLM3): a prospective population-based diagnostic study","volume":"16","author":"Gronberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0695","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.eururo.2018.06.022","article-title":"Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging","volume":"74","author":"Gronberg","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0700","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0705","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1634\/theoncologist.2015-0336","article-title":"The PROFILE feasibility study: targeted screening of men with a family history of prostate cancer","volume":"21","author":"Castro","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2019.04.033_bib0710","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2018.05.032","article-title":"Value of a statistical model based on four kallikrein markers in blood, commercially available as 4Kscore, in all reasonable prostate biopsy subgroups","volume":"74","author":"Vickers","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0715","first-page":"149","article-title":"Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: a meta-analysis of us and European clinical validation study results","volume":"19","author":"Zappala","year":"2017","journal-title":"Rev Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0720","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bju.13676","article-title":"Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer","volume":"120","author":"Loeb","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.04.033_bib0725","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","article-title":"Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score","volume":"70","author":"Van Neste","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0730","doi-asserted-by":"crossref","first-page":"e3840201","DOI":"10.1371\/journal.pone.0201384","article-title":"Optimizing patient's selection for prostate biopsy: a single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer","volume":"13","author":"Punnen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2019.04.033_bib0735","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.urology.2016.08.022","article-title":"Risk stratification by urinary prostate cancer gene 3 testing before magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy among men with no history of biopsy","volume":"99","author":"Fenstermaker","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.04.033_bib0740","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.eururo.2018.06.008","article-title":"Active surveillance for low-risk prostate cancer: the European Association of Urology position in 2018","volume":"74","author":"Briganti","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0745","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0750","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.euf.2017.07.003","article-title":"Trends in radical prostatectomy risk group distribution in a European multicenter analysis of 28572 patients: towards tailored treatment","volume":"5","author":"van den Bergh","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2019.04.033_bib0755","doi-asserted-by":"crossref","unstructured":"Mahal BA, Butler S, Franco I, et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010\u20132015. JAMA. In press. DOI: 10.1001\/jama.2018.19941.","DOI":"10.1001\/jama.2018.19941"},{"key":"10.1016\/j.eururo.2019.04.033_bib0760","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0765","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0770","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2018.01.001","article-title":"Focal therapy in primary localised prostate cancer: the European Association of Urology Position in 2018","volume":"74","author":"van der Poel","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0775","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1001\/jama.2013.277514","article-title":"Variation among primary care physicians in prostate-specific antigen screening of older men","volume":"310","author":"Jaramillo","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2019.04.033_bib0780","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/cncr.28600","article-title":"National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making","volume":"120","author":"Drazer","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.04.033_bib0785","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bju.12892","article-title":"Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool","volume":"117","author":"Gaziev","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.04.033_bib0790","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.juro.2018.06.012","article-title":"The institutional learning curve of magnetic resonance imaging-ultrasound fusion targeted prostate biopsy: temporal improvements in cancer detection in 4 years","volume":"200","author":"Meng","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0795","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urpr.2017.03.009","article-title":"Prostate multiparametric magnetic resonance imaging program implementation and impact: initial clinical experience in a community based health system","volume":"3","author":"Farrell","year":"2018","journal-title":"Urol Pract"},{"key":"10.1016\/j.eururo.2019.04.033_bib0800","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10654-017-0292-5","article-title":"A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale","volume":"32","author":"Auvinen","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0805","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.eururo.2016.03.026","article-title":"Screening for prostate cancer starting at age 50\u201354 years. A population-based cohort study","volume":"71","author":"Carlsson","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.04.033_bib0810","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.eururo.2013.05.022","article-title":"Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial","volume":"64","author":"Arsov","year":"2013","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819303471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819303471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T10:16:08Z","timestamp":1563012968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283819303471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0302283819303471"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2019.04.033","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2019.04.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}